🇺🇸 FDA
Patent

US 8414890

Human antibodies to human RANKL, encoding nucleic acids and methods of treatment

granted A61KA61K2039/505A61P

Quick answer

US patent 8414890 (Human antibodies to human RANKL, encoding nucleic acids and methods of treatment) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/505, A61P, A61P19/00, A61P19/02